On 9/27/13, Essex Property Trust, Inc.'s 7.125% Series H Cumulative Redeemable Preferred Stock (ESS.PRH) will trade ex-dividend, for its quarterly dividend of $0.4453, payable on 10/15/13. As a percentage of ESS.PRH's recent share price of $25.53, this dividend works out to approximately 1.74%, so look for shares of ESS.PRH to trade 1.74% lower — all else being equal — when ESS.PRH shares open for trading on 9/27/13. On an annualized basis, the current yield is approximately 6.98%, which compares to an average yield of 7.50% in the "Real Estate" preferred stock category, according to Preferred Stock Channel.As of last close, ESS.PRH was trading at a 2.04% premium to its liquidation preference amount.The chart below shows the one year performance of ESS.PRH shares, versus ESS: Below is a dividend history chart for ESS.PRH, showing historical dividends prior to the most recent $0.4453 on Essex Property Trust, Inc.'s 7.125% Series H Cumulative Redeemable Preferred Stock: According to the ETF Finder at ETF Channel, Essex Property Trust, Inc. ( ESS - Get Report) makes up 4.02% of the iShares Residential Real Estate Capped ETF (REZ) which is trading relatively unchanged on the day Wednesday. In Wednesday trading, Essex Property Trust, Inc.'s 7.125% Series H Cumulative Redeemable Preferred Stock ( ESS.PRH) is currently up about 0.1% on the day, while the common shares ( ESS - Get Report) are up about 0.1%.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Ear to the Ground on UTX-Raytheon: What Needs to Happen for the Deal to Close
Shareholders are skittish about this deal, one analyst said. See why they shouldn't be.
AbbVie Rebounds as Market Warms to Allergan Deal, Botox Potential
AbbVie's deal for Allergan will give it a new revenue stream in Botox, helping offset potential lower revenue from arthritis drug Humira, which is losing patent protection.
Care.com Shares Slump After Chief Financial Officer Resigns
Care.com's finance chief resigns a few months after a Wall Street Journal report that many day-care centers listed on the company's site were unlicensed.
Dow Ends Down on Mixed Trade Messages From Mnuchin, Trump
Stocks end mixed after Treasury Secretary Steven Mnuchin says the U.S. and China were close to reaching a trade agreement, while President Trump hints that he wants to make a trade deal with Beijing but is happy where things are now.